Author: Michael Day

Myriad Genetics’ Flurizan (taren_urbil), the first in a new class of Alzheimer’s treatments, has almost halved the rates at which symptoms progressed in a Phase II study of patients with mild forms of the dementia.

As a leading hepatologist has revealed more good news for Gilead’s HIV-turned-hepatitis B treatment Viread (tenofovir), the drug received European approval for treating the liver disease

Patients safety incidents cost the US federal Medicare program $8.8 billion and

Drugs fast-tracked by the US Food and Drug Administration are three times more likely to be withdrawn later than medicines approved at normal speed, according to a Harvard University study.

A leading cancer surgeon has described Ferring’s new prostate cancer drug degarelix, as a “breakthrough” on the basis of fresh Phase III results.